Home / Knowledge Center /
Technical Publication

Application of Radionuclides and Antibody-Drug Conjugates to Target Cancer

Radionuclide therapy and antibody-drug conjugates are used to locate and kill cancer cells by the utilization of monoclonal antibodies. These bio-vectors are able to transport a cytotoxic drug payload and/or radiation in the form of alpha or beta particles to bind onto antigen specific cancer cells initiating apoptosis.
This inaugural article aims to deliver a brief account of these targeted therapies in the treatment of oncological disease states such as leukemia, non-Hodgkin’s lymphoma, neuroendocrine tumors, breast cancer and prostate cancer bone metastases.

View Resource
Almac Logo

Almac API, Chemical Development, Analytical & Solid State Services

Almac Sciences provides integrated services from development to commercial scale of advanced intermediates and Active Pharmaceutical Ingredients (API).

We provide a range of services for small molecules (including highly potent) and peptides. We have a proven track record of saving time and cost through the integration of our services and application of innovative biocatalysis and technology solutions.

Learn More

We offer a full suite of analytical testing for a range of different product types including small molecules, peptides, biologics, conjugates, potent and controlled substances.

Our vast pool of scientific knowledge can help to overcome the analytical challenges that typically arise during drug development.

Learn More

Download here instantly

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies